OmniAb (OABI) Insider John Higgins Sells 20,000 Shares

Insider Buying and Selling at OmniAb, Inc.

On June 17, 2026, John Higgins, an insider at OmniAb, Inc. (OABI), sold 20,000 shares at a price of $2.34 each. This transaction is valued at about $46,800. Notably, Higgins was not alone in this move; several other insiders also executed trades on the same day.

Multiple Insiders Active on June 17

In addition to John Higgins, other insiders at OmniAb also sold shares on June 17. Steven Love sold 20,000 shares, while Philip Gotwals and Steven Crouse each sold 20,000 shares as well. Meanwhile, Steven Crouse also made a purchase of 20,000 shares, and Steven Love acquired 40,000 shares. These simultaneous actions highlight a mix of sentiment among the company's insiders.

Stock Performance Context

As of June 17, 2026, OmniAb's stock was trading at $2.34, close to its 52-week low of $1.30. The stock has seen a high of $5.43 over the past year. This positioning may concern investors, especially with the stock trading below its 200-day moving average of about $2.29. The upcoming earnings report on November 4, 2026, will be crucial for assessing the company's performance and future direction, as analysts maintain a fairly optimistic outlook with a mean price target of $8.40.

Recent Earnings

For the quarter ended March 31, 2026, OmniAb reported revenue of $38.5 million, showing a revenue growth of 2.44%. The company has been struggling with profitability, posting an EPS of -$0.36 and a net margin of -1.15%. These figures will be important for investors to consider as they await the next earnings report.

Analysts Set New Price Targets

Analysts are divided on OmniAb's future. On October 7, 2026, Leerink Partners maintained an "Outperform" rating with a price target of $12.00, up from a prior target of $10.00. StoneX also maintained a "Buy" rating, raising its target from $4.00 to $6.00. HC Wainwright & Co. reiterated a "Buy" rating with a target of $11.00. With five analysts covering the stock, the average target price suggests room for growth despite current challenges.

What OmniAb, Inc. Does

OmniAb, Inc. is a biotechnology company based in Emeryville, California. It focuses on providing technology that helps pharmaceutical and biotech firms discover new therapeutics. The company's innovative platforms create a diverse range of antibody candidates, aiding in drug development.

What to Watch

Investors should keep an eye on the upcoming earnings report on November 4, 2026, for insights into OmniAb's financial health. Additionally, the recent insider trading activity may provide further context on the company's future direction. Remember, the insider trades reflect positions as of June 17 and may not represent current holdings.